Evidence map›Paper›PMID 37205485›Full record

ArticlebioRxiv : the preprint server for biology2023

Parallel Evolution of Linezolid Resistant

Nicholas J Pitcher, Andries Feder, Nicholas Bolden, Christian F Zirbes, Anthony J Pamatmat, Linda Boyken, Jared J Hill, Andrew L Thurman, Valérie C Reeb, Harry S Porterfield and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Nicholas J PitcherStead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA 52242.
Andries FederChildren's Hospital of Philadelphia, Philadelphia, PA 19104.
Nicholas BoldenPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Christian F ZirbesStead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA 52242.
Anthony J PamatmatStead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA 52242.
Linda BoykenPathology. University of Iowa Carver College of Medicine, Iowa City, IA 52242.
Jared J HillStead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA 52242.
Andrew L ThurmanInternal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA 52242.
Valérie C ReebState Hygienic Laboratory at the University of Iowa, Coralville, IA 52241.
Harry S PorterfieldMicrobiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Ahmed M MoustafaChildren's Hospital of Philadelphia, Philadelphia, PA 19104.
Paul J PlanetChildren's Hospital of Philadelphia, Philadelphia, PA 19104.
Anthony J FischerStead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA 52242.
University of Iowa · USChildren's Hospital of Philadelphia · USNational Institutes of Health Clinical Center · USUniversity of Pennsylvania · US

Funding

The University of Iowa Clinical and Translational Science AwardUL1TR002537 · NCATS · UNIVERSITY OF IOWA · PI HANSEN, MARLAN R, WINOKUR, PATRICIA · 2018 to 2022
$20.0M
Bacterial Interference to Prevent Staphylococcus aureus InfectionR01AI137526 · NIAID · CHILDREN'S HOSP OF PHILADELPHIA · PI PLANET, PAUL J · 2018 to 2021
$1.7M
Initial Attachment of Bacteria to Mucus Strands in Cystic FibrosisK08HL136927 · NHLBI · UNIVERSITY OF IOWA · PI FISCHER, ANTHONY JOHN · 2017 to 2020
$639k
NCATS NIH HHS UL1 TR002537NHLBI NIH HHS K08 HL136927NIAID NIH HHS R01 AI137526
6 · The paper itself

Abstract

Background: Linezolid is an antibiotic used to treat serious Objectives: The goals of this study were to determine the incidence of linezolid resistance in CF and identify molecular mechanisms for linezolid resistance. Methods: We identified patients with Main Results: Between 2008 and 2018, 111 patients received linezolid and 4 of these patients cultured linezolid resistant Conclusions: Linezolid resistance evolved in 4 of 111 patients in this study. Linezolid resistance occurred by multiple genetic mechanisms. All resistant strains developed in ST5 or ST105 MRSA backgrounds. Key Point: Linezolid resistance arises through multiple genetic mechanisms and could be facilitated by mutator phenotypes. Linezolid resistance was transient, possibly due to growth disadvantage.

Identifiers

PMID37205485
PMCPMC10187253
OpenAlexW4367845557

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.